SCHEMBL963820

SCHEMBL963820

Cc1ccc(S(=O)(=O)N(Cc2c(C)nn(C)c2-n2ccc3cc(Cl)ccc32)C(=O)O)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 1/20 0.38
KEAP1 Q14145 1/20 0.37
NFE2L2 Q16236 1/20 0.37
PPARG P37231 1/20 0.37
PPARD Q03181 1/20 0.37
PHGDH O43175 3/20 0.35
PSEN1 P49768 3/20 0.35
PSEN2 P49810 3/20 0.35
APH1B Q8WW43 3/20 0.35
NCSTN Q92542 3/20 0.35
APH1A Q96BI3 3/20 0.35
PSENEN Q9NZ42 3/20 0.35
PTGER1 P34995 1/20 0.35
MCOLN3 Q8TDD5 1/20 0.35
LMNA P02545 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
CNR2 P34972 1/20 0.34
NPC1 O15118 1/20 0.34
GALR3 O60755 1/20 0.34
NR2F2 P24468 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL963605 0.94 TRPM8 (0.41) TRPM8KEAP1NFE2L2PPARGPPARD
SCHEMBL963628 0.92 TAS2R14 (0.40) TRPM8KEAP1NFE2L2PPARGLMNA
SCHEMBL966630 0.83 PTGDR2 (0.34) TRPM8PPARGPHGDH
SCHEMBL967888 0.80 MAPK8 (0.34) TRPM8PPARGPPARDPHGDHLMNA
SCHEMBL966982 0.80 PHGDH (0.34) PHGDHLMNASMN1; SMN2HTT
SCHEMBL963395 0.79 KMT2A (0.37) TRPM8PHGDHSMN1; SMN2
SCHEMBL966868 0.78 SLC6A2 (0.35) TRPM8PHGDHLMNASMN1; SMN2NR2F2
SCHEMBL961690 0.78 MAPT (0.49) LMNASMN1; SMN2NPC1RAB9A
SCHEMBL961862 0.78 PTGDR2 (0.48)
SCHEMBL967867 0.78 PHGDH (0.35) PHGDHLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110009384-A1 FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA TAKEDA PHARMACEUTICAL COMPANY LIMITED 2011-01-13 US disclosed
US-20080194617-A1 Fused ring compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-08-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194617-A1 Fused ring compound SLC5A1, SLC5A2, GPR119 TRPM8 3343/4885KEAP1 300/4885NFE2L2 1374/4885
US-20110009384-A1 FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA PPARA, PPARD, PPARG TRPM8 1651/4885KEAP1 1826/4885NFE2L2 2166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.